Skip to content
etf.net

Launched · SEC filings

Virtus Biotech ETF

BBPNYSE ArcaA

$100.81−2.82 (−2.73%)

As of Oct 13, 2026, 3:58 PM

A75/ 100

Rank 3 of 17 in Biotech & Genomics

A75/100Rank 3 of 17inBiotech & Genomics
Intraday session: down, 50 prints from 103.63 to 100.81. Range 100.81 to 103.01. Use the arrow keys to read each point.101.50102.00102.50103.0010 AM12 PM2 PM4 PM
Expense ratio
0.34%
Fund size
$131M
1Y total return
+47.9%
Yield · Last 12 months
0.00%
Holdings
66
Avg volume · 30D
0M sh
NAV per share
$104.84
52W range
low $70.30high $110.05
Launched
Filings
SEC EDGAR

The ETF.net BBP Grade

A

Score 75 out of 100

Category
Biotech & Genomics⁠
Rank
3 of 17
Six-pillar profile for BBP. Scores out of 100: Cost 94, Risk 69, Mission 84, Tradability 31, Holdings 83, Durability 57. Strongest: Cost (94). Weakest: Tradability (31). Leans toward Cost.

Score 75 of 100 falls in the A band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    A94 out of 100
    Rank 2 of 17

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    A84 out of 100
    Rank 4 of 9

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    B69 out of 100
    Rank 4 of 17

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    D31 out of 100
    Rank 13 of 17

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    A83 out of 100
    Rank 3 of 17

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    B57 out of 100
    Rank 8 of 17

Our read on BBP

ETF.net Research

ABiotech, minus the coin flips. BBP tracks an index of US-listed biotech companies that already have at least one FDA-approved therapy, so the basket leans commercial-stage instead of clinical-trial hopefuls.

Stated mandate

The fund seeks to track the LifeSci Biotechnology Products Index, which consists of U.S.-listed biotechnology stocks with at least one FDA-approved drug therapy.

Why people hold it

  1. 01The screen does the heavy lifting: index membership requires at least one FDA-approved drug therapy, which filters out pre-approval story stocks.
  2. 020.34% a year undercuts the biotech cohort median of 0.50% and sits below IBB's 0.44%.
  3. 03Running since 2014 and spread across roughly 200 US-listed names, so one approval or rejection does not decide the whole basket.
  4. 04One of the stronger builds in its biotech and genomics peer group, with a portfolio that stays close to the index it promises.

Worth knowing

  1. 01Thinly traded and modest in size next to the category's household names. Spreads can widen, which makes limit orders the safer habit.
  2. 02Income is not the point here. The fund has not been paying distributions, so the return story is price.
  3. 03An approved drug filters risk, it does not erase it. This is a single-sector biotech basket, and sector drawdowns hit everything in it.

BBP Holdings

As of Oct 13, 2026
Asset class
Stocks
Holdings
66
Top-10 weight
28%
Largest holding
MRNA5.8%

Sectors

  • Health Care100.0%

Geography

  • United States85.80%
  • United Kingdom4.88%
  • Switzerland3.22%
  • China1.97%
  • Denmark1.39%
  • Germany1.39%
  • Canada1.34%
The fund’s holdings, weight-ordered — page 1 of 5.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001MRNAModerna Inc5.80%33,770$8M286
002IOVAIovance Biotherapeutics Inc4.61%413,111$6M91
003OMEROmeros Corp2.92%192,959$4M56
004VSTMVerastem Inc2.63%411,097$3M39
005PGENPrecigen Inc2.26%378,763$3M69
006HALOHalozyme Therapeutics Inc2.04%24,252$3M208
007XERSXeris Biopharma Holdings Inc1.99%248,233$3M68
008KNSAKiniksa Pharmaceuticals International Plc1.98%32,483$3M82
009RIGLRigel Pharmaceuticals Inc1.92%51,309$3M74
010IBRXImmunityBio Inc1.90%237,394$2M79
011ZLABZai Lab Ltd1.88%98,741$2M14
012NVAXNovavax Inc1.85%189,808$2M68
013BGNEBeOne Medicines Ltd1.72%6,373$2M1
014PTGXProtagonist Therapeutics Inc1.68%15,354$2M145
015ADMAADMA Biologics Inc1.62%205,298$2M110

Showing 1–15 of 66 holdings

BBP Performance

Launched Dec 16, 2014

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

BBP$14,788
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$12,044
Oct 10, 2025 to Oct 12, 2026. BBP $14,788. SPY $12,044. Use the arrow keys to read each point.$9,305$12,644$15,983Oct 2025Apr 2026Oct 2026

Oct 10, 2025 – Oct 12, 2026

Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for BBP. Periods over one year show the average yearly return.
PeriodBBP
Year to date+31.0%
1 month+1.2%
3 months+4.4%
1 year+47.9%
3 yearsper year+29.5%
5 yearsper year+15.7%
10 yearsper year+12.8%

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for BBP
YearReturn barBBP
2026 YTD+31.0%
2025+33.1%
2024+3.3%
2023+17.9%
2022+0.9%
2021−8.2%
2020+22.2%

BBP in the news

Filtered to BBP · Biotech & Genomics

BBP Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 12, 2026.
0.00%Last 12 months
Payout per share
NoneLast 12 months

No distributions in the last 12 months.

Distribution history

Payments through 2017

One bar per payment. 2 payments from 2015 to 2017. Dec 21, 2015 $0.40; Dec 20, 2017 $0.07. Use the arrow keys to read each point.201520162017
Ex-datePay dateAmount per share
Dec 20, 2017Dec 27, 2017$0.07
Dec 21, 2015Dec 29, 2015$0.40

BBP Risk

How much the fund’s monthly returns vary, scaled to a year.
19.3%
Annualised · 36 months to Sep 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
1.16
vs 3-month T-bills · to Sep 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−37.8%
Trough May 2022
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.85
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

BBP Cost

Expense ratio0.34%
  • The middle half of Biotech & Genomics funds
  • Median 0.47%

1 of the 17 Biotech & Genomics funds charge less.

BBP costs $34.00 a year on $10,000. The median Biotech & Genomics fund costs $47.00.

Other funds in Biotech & Genomics

See others